PD-1 Round-Up: Big Pharmas Talk Competitive Positioning
Executive Summary
During first-quarter earnings calls, sponsors of PD-1/L1 immunotherapies defend their positions in the wake of new data and filings in April, and ahead of the annual ASCO meeting.